先聲藥業(02096.HK)：抗新冠創新藥先諾欣®(先諾特韋片╱利托那韋片組合包裝)新藥上市申請獲國家藥監局受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)：抗新冠創新藥先諾欣®(先諾特韋片╱利托那韋片組合包裝)新藥上市申請獲國家藥監局受理

格隆匯 01-16 16:35

格隆匯1月16日丨先聲藥業(02096.HK)發佈公吿，2023年1月16日，集團與中國科學院上海藥物研究所、武漢病毒研究所合作的創新藥先諾欣^®(先諾特韋片╱利托那韋片組合包裝)新藥上市申請(“NDA”)獲中國國家藥品監督管理局(“NMPA”)以藥品特別審批程序受理，擬用於治療輕至中度新型冠狀病毒感染(“COVID-19”)成年患者。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)：抗新冠創新藥先諾欣®(先諾特韋片╱利托那韋片組合包裝)新藥上市申請獲國家藥監局受理

Services

About Us

Agreement Statement